Royal Bank of Canada’s Innate Pharma IPHA Stock Holding History

Royal Bank of Canada’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-124	Closed	–	–	7435
2023 Q1	$0	Sell	124 -1	-0.8%	-$3	﹤0.01%	7260
2022 Q4	$0	Sell	125 -52	-29%	-$118	﹤0.01%	7456
2022 Q3	$0	Buy	+177	New	+$478	﹤0.01%	7628

Other funds holding IPHA

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada's IPHA Position: Q2 2023 in Review

Royal Bank of Canada sold out of Innate Pharma (IPHA) in Q2 2023, closing a stake of 124 shares.

Royal Bank of Canada first reported a position in IPHA in Q3 2022 and held it in 3 quarters. The position peaked at $0 in Q1 2023. 9 funds tracked by Wall St. Rank hold IPHA as of Q2 2023.

Royal Bank of Canada reported no remaining Innate Pharma position as of Q2 2023 after selling out during the quarter.
Royal Bank of Canada sold 124 Innate Pharma shares in Q2 2023.
Royal Bank of Canada first reported a position in Innate Pharma in Q3 2022 and held it in 3 quarters.
Royal Bank of Canada's Innate Pharma position peaked at $0 in Q1 2023.
9 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2023.

Based on Royal Bank of Canada's 13F filing for Q2 2023, filed 14 Aug 2023.